Skip to main content

Table 1 Demographic data

From: Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study

  SScPAH+ N = 11 SScPAH- N = 13 Control N = 10
Age, yr 70.1 ± 9.6 66.2 ± 11.2 59.7 ± 6.5
Height, m 1.6 ± 0.1 1.7 ± 0.1 1.7 ± 0.1
Male/Female 0/9 0/12 2/8
Limited cutaneous SSc (%) 100 100  
Haemoglobin, mmol/l 7.8 ± 1.2 8.0 ± 0.6 8.6 ± 0.8
Raynaud's phenomenon (%) 100 92  
Raynaud's phenomenon at PFT, years 19.2 ± 10.6* 6.6 ± 8.3  
Autoantibodies (no.)   12  
ANA 10 6  
Anti-centromere 7 5  
Anti-topoisomerase 0   
Modified Rodnan skin score 14.1 ± 5.7 11.9 ± 5.9  
Smoking status 7/3/1 6/4/2 8/2/0
Never/former/current (no.)    
6-minute walking distance, m 326 ± 102 430 ± 127  
SvO2, % 62.7 ± 6.6* 72.5 ± 2.0  
HRCT fibrosis score‡ 4.9 ± 3.4 4.1 ± 3.4  
HRCT ground glass score‡ 7.1 ± 5.8 3.1 ± 5.5  
HRCT total fibrosis score 12.1 ± 6.8 7.4 ± 8.5  
  1. Values expressed as mean ± SD, otherwise as stated. Abbreviations: SScPAH+: systemic sclerosis associated pulmonary arterial hypertension. SScPAH-: SSc without PAH;. PFT: pulmonary function testing; ANA: anti-nucleolar antibodies.. SvO2: mixed venous oxygen saturation. * p < 0.05 for comparison of SScPAH+ with SScPAH-; According to reference 23. According to reference 24.